AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
Go back to AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia| AbbVie (NYSE: ABBV) | Delayed: 231.46 +14.97 (6.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $216.49 | 52 Week High | $68.12 | |||
| Open | $221.94 | 52 Week Low | $50.71 | |||
| Day High | $232.32 | P/E | 50.21 | |||
| Day Low | $221.94 | EPS | $4.61 | |||
| Volume | 4,978,887 | |||||
